South Korea · Delayed Price · Currency is KRW Biotoxtech Statistics
Total Valuation
Biotoxtech has a market cap or net worth of KRW 34.82 billion. The enterprise value is 62.44 billion.
| Market Cap | 34.82B |
| Enterprise Value | 62.44B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biotoxtech has 15.72 million shares outstanding. The number of shares has decreased by -1.73% in one year.
| Current Share Class | 15.72M |
| Shares Outstanding | 15.72M |
| Shares Change (YoY) | -1.73% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 15.15% |
| Owned by Institutions (%) | n/a |
| Float | 10.36M |
Valuation Ratios
The trailing PE ratio is 44.77.
| PE Ratio | 44.77 |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| PB Ratio | 1.19 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | 9.76 |
| P/OCF Ratio | 5.24 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 81.19 |
| EV / Sales | 1.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 17.51 |
Financial Position
The company has a current ratio of 0.53, with a Debt / Equity ratio of 2.13.
| Current Ratio | 0.53 |
| Quick Ratio | 0.39 |
| Debt / Equity | 2.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | 17.44 |
| Interest Coverage | -1.15 |
Financial Efficiency
Return on equity (ROE) is -7.21% and return on invested capital (ROIC) is -9.55%.
| Return on Equity (ROE) | -7.21% |
| Return on Assets (ROA) | -2.99% |
| Return on Invested Capital (ROIC) | -9.55% |
| Return on Capital Employed (ROCE) | -14.81% |
| Weighted Average Cost of Capital (WACC) | 6.84% |
| Revenue Per Employee | 253.38M |
| Profits Per Employee | 4.09M |
| Employee Count | 188 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 4.08 |
Taxes
In the past 12 months, Biotoxtech has paid 1.34 billion in taxes.
| Income Tax | 1.34B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.04% in the last 52 weeks. The beta is 0.43, so Biotoxtech's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -19.04% |
| 50-Day Moving Average | 2,961.30 |
| 200-Day Moving Average | 2,918.63 |
| Relative Strength Index (RSI) | 28.54 |
| Average Volume (20 Days) | 43,135 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biotoxtech had revenue of KRW 47.64 billion and earned 769.13 million in profits. Earnings per share was 49.48.
| Revenue | 47.64B |
| Gross Profit | 5.57B |
| Operating Income | -6.31B |
| Pretax Income | -887.30M |
| Net Income | 769.13M |
| EBITDA | -1.92B |
| EBIT | -6.31B |
| Earnings Per Share (EPS) | 49.48 |
Balance Sheet
The company has 25.52 billion in cash and 62.19 billion in debt, with a net cash position of -36.67 billion or -2,332.74 per share.
| Cash & Cash Equivalents | 25.52B |
| Total Debt | 62.19B |
| Net Cash | -36.67B |
| Net Cash Per Share | -2,332.74 |
| Equity (Book Value) | 29.25B |
| Book Value Per Share | 2,485.92 |
| Working Capital | -41.32B |
Cash Flow
In the last 12 months, operating cash flow was 6.64 billion and capital expenditures -3.07 billion, giving a free cash flow of 3.57 billion.
| Operating Cash Flow | 6.64B |
| Capital Expenditures | -3.07B |
| Depreciation & Amortization | 4.39B |
| Net Borrowing | -5.84B |
| Free Cash Flow | 3.57B |
| FCF Per Share | 226.88 |
Margins
Gross margin is 11.70%, with operating and profit margins of -13.25% and 1.61%.
| Gross Margin | 11.70% |
| Operating Margin | -13.25% |
| Pretax Margin | -1.86% |
| Profit Margin | 1.61% |
| EBITDA Margin | -4.04% |
| EBIT Margin | -13.25% |
| FCF Margin | 7.49% |
Dividends & Yields
Biotoxtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.73% |
| Shareholder Yield | 1.73% |
| Earnings Yield | 2.21% |
| FCF Yield | 10.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biotoxtech has an Altman Z-Score of 0.09 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.09 |
| Piotroski F-Score | 6 |